Analyzing CG Oncology (NASDAQ:CGON) & Silexion Therapeutics (NASDAQ:SLXN)

CG Oncology (NASDAQ:CGON) and Silexion Therapeutics (NASDAQ:SLXN) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, valuation, earnings, dividends, institutional ownership, risk and analyst recommendations.

Profitability

This table compares CG Oncology and Silexion Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CG Oncology	-10,642.98%	-18.97%	-15.36%
Silexion Therapeutics	N/A	N/A	-249.43%

Valuation & Earnings

This table compares CG Oncology and Silexion Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CG Oncology	$684,000.00	2,789.17	-$48.61 million	N/A	N/A
Silexion Therapeutics	N/A	N/A	$260,000.00	N/A	N/A

Silexion Therapeutics has lower revenue, but higher earnings than CG Oncology.

Insider & Institutional Ownership

26.6% of CG Oncology shares are owned by institutional investors. Comparatively, 10.9% of Silexion Therapeutics shares are owned by institutional investors. 33.0% of Silexion Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for CG Oncology and Silexion Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CG Oncology	0	0	8	1	3.11
Silexion Therapeutics	0	0	1	0	3.00

CG Oncology currently has a consensus target price of $65.14, suggesting a potential upside of 159.64%. Silexion Therapeutics has a consensus target price of $9.00, suggesting a potential upside of 682.61%. Given Silexion Therapeutics’ higher possible upside, analysts clearly believe Silexion Therapeutics is more favorable than CG Oncology.

Summary

CG Oncology beats Silexion Therapeutics on 6 of the 11 factors compared between the two stocks.

About CG Oncology

CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.

About Silexion Therapeutics

Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel.